Tim Anderson
Stock Analyst at B of A Securities
(4.12)
# 497
Out of 5,115 analysts
50
Total ratings
66.67%
Success rate
11.06%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Maintains: Neutral | $220 → $221 | $227.29 | -2.77% | 10 | Jan 22, 2026 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,286 → $1,268 | $1,024.14 | +23.81% | 2 | Dec 15, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $105 → $120 | $108.34 | +10.76% | 5 | Dec 15, 2025 | |
| BMY Bristol-Myers Squibb Company | Upgrades: Buy | $52 → $61 | $54.28 | +12.38% | 2 | Dec 15, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Underperform | $543 → $627 | $749.44 | -16.34% | 3 | Oct 29, 2025 | |
| PFE Pfizer | Maintains: Neutral | $28 → $30 | $26.10 | +14.94% | 3 | Oct 3, 2025 | |
| AMGN Amgen | Maintains: Underperform | $261 → $272 | $342.94 | -20.69% | 6 | Sep 26, 2025 | |
| APGE Apogee Therapeutics | Maintains: Buy | $78 → $87 | $69.98 | +24.32% | 1 | Aug 28, 2025 | |
| AARD Aardvark Therapeutics | Maintains: Buy | $26 → $25 | $13.35 | +87.27% | 3 | Aug 28, 2025 | |
| ABBV AbbVie | Maintains: Neutral | $200 → $204 | $220.43 | -7.45% | 7 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $116 → $126 | $139.55 | -9.71% | 3 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $41 → $34 | $46.86 | -27.44% | 2 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $178 | $176.18 | +1.03% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $148.91 | - | 1 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $92.59 | - | 1 | Sep 22, 2017 |
Johnson & Johnson
Jan 22, 2026
Maintains: Neutral
Price Target: $220 → $221
Current: $227.29
Upside: -2.77%
Eli Lilly and Company
Dec 15, 2025
Maintains: Buy
Price Target: $1,286 → $1,268
Current: $1,024.14
Upside: +23.81%
Merck & Co.
Dec 15, 2025
Maintains: Buy
Price Target: $105 → $120
Current: $108.34
Upside: +10.76%
Bristol-Myers Squibb Company
Dec 15, 2025
Upgrades: Buy
Price Target: $52 → $61
Current: $54.28
Upside: +12.38%
Regeneron Pharmaceuticals
Oct 29, 2025
Maintains: Underperform
Price Target: $543 → $627
Current: $749.44
Upside: -16.34%
Pfizer
Oct 3, 2025
Maintains: Neutral
Price Target: $28 → $30
Current: $26.10
Upside: +14.94%
Amgen
Sep 26, 2025
Maintains: Underperform
Price Target: $261 → $272
Current: $342.94
Upside: -20.69%
Apogee Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $78 → $87
Current: $69.98
Upside: +24.32%
Aardvark Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $26 → $25
Current: $13.35
Upside: +87.27%
AbbVie
Apr 28, 2025
Maintains: Neutral
Price Target: $200 → $204
Current: $220.43
Upside: -7.45%
Mar 5, 2025
Maintains: Buy
Price Target: $116 → $126
Current: $139.55
Upside: -9.71%
Feb 11, 2025
Maintains: Underperform
Price Target: $41 → $34
Current: $46.86
Upside: -27.44%
Dec 10, 2024
Reinstates: Neutral
Price Target: $178
Current: $176.18
Upside: +1.03%
May 9, 2022
Downgrades: Peer Perform
Price Target: n/a
Current: $148.91
Upside: -
Sep 22, 2017
Upgrades: Outperform
Price Target: n/a
Current: $92.59
Upside: -